EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...
Black men often cite not being asked as the primary reason for not participating in prostate cancer clinical trials. Only 10.4% of surveyed Black men with prostate cancer had participated in clinical ...
"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...
"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...
“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS. In this video, Adam Lorentz, MD, FACS, ...
Fast track designation for 64Cu-SAR-bisPSMA enables accelerated development and review for prostate cancer imaging. Phase 1/2 COBRA trial showed 64Cu-SAR-bisPSMA's efficacy in detecting lesions missed ...
As this is a balloon, the question has come up on whether it would be appropriate to report Current Procedural Terminology (CPT) code 55874 (Transperineal placement of biodegradable material, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback